Worldleish

An International Congress on Leishmania & Leishmaniasis

Why ?  Cutaneous, mucocutaneous and visceral leishmaniases are serious diseases, which are vector-borne and wide-spread in more than 90 countries, putting 350 million population at risk. WHO estimates an annual incidence of 2 million and a total of 12 million current cases. The causative agents are various species of trypanosomatid protozoa in the genus of Leishmania, which are excellent models for aspects of laboratory studied in cell/molecular biology, biochemistry, immunology of host-parasite interactions.

Who ? Anyone interested in Leishmania and leishmaniasis is welcome to participate, including individuals of private and public academic institutions, charitable organizations, advocacy groups, government officials/ representatives, for-profit private sectors and their friends/affiliates.

 When/where ? Every four years preferably in a country endemic to leishmaniasis.

What ? Bring laboratory researchers and field workers from all disciplinary areas together for sharing new discoveries and exchange of new ideas. Provide opportunities of international collaboration, industrial participation, charitable donation and training of the next generation.

Dear colleagues,

Registration is now open for the next edition of WorldLeish, the premier congress for leishmaniasis expected to attract around 1500 participants including scientific experts and health decision-makers, WHO representatives, and governments representatives from endemic countries, and all major organizations involved in the fight against leishmaniasis. 

Submit your abstract by the 30 November deadline and save the date to join us in Toledo, Spain, on 16-20th May 2017.

Co-organized by the WHO Collaborating Centre for Leishmaniasis of the Instituto de Salud Carlos III (Madrid, Spain) and the Drugs for Neglected Diseases initiative (DNDi, Geneva, Switzerland), the Congress scientific programme will cover all scientific and policy aspects of leishmaniasis today:
- from basic research to disease control and elimination - as targeted by the WHO Roadmap for Neglected Tropical Diseases and the 2012 'London Declaration';
- with a focus on patients' needs but also sessions on canine leishmaniasis and vector research;
- with dedicated symposia on drug discovery, trial standardisation, and advocacy to discuss the way forward with experts and key actors;

WorldLeish is also partnering with PLOS journals on a Special Collection on leishmaniasis that will compile publications on the key topics discussed at the Congress. Submission for articles is now open, with publication of the first articles in the series (which will be updated until the Congress) coming soon. More information:
http://blogs.plos.org/collections/call-for-papers-worldleish6/

We look forward to welcoming you in Toledo,

Dr Jorge Alvar, chair, and Dr Javier Moreno, co-chair
on behalf of the Organizing Committee of WL6


http://www.worldleish2017.org